TY  - JOUR
T1  - Managing Biopharmaceutical Variability without Demanding Manufacturing Sameness through Lifecycle Evidence, Process Understanding, Change Control, and Product Evolution
A1  - Luca Ferraro
A1  - Matteo Ricci
A1  - Giulia Moretti
A1  - Paolo Greco
JF  - International Journal of Pharmaceutical Research and Allied Sciences
JO  - Int J Pharm Res Allied Sci
SN  - 2277-3657
Y1  - 2025
VL  - 14
IS  - 3
DO  - 10.51847/j1CJ5gdQVa
SP  - 64
EP  - 72
N2  - Biopharmaceuticals are heterogeneous products whose molecular distributions may vary across batches, manufacturing sites, process states, storage periods, analytical platforms, and delivery configurations. Lifecycle assurance should therefore focus less on preserving historical manufacturing sameness and more on determining whether product evolution remains compatible with clinically relevant quality, safety, efficacy, exposure, and immunogenicity expectations. This article proposes a non-empirical Lifecycle Variability-Control Architecture that integrates product-state knowledge, process understanding, critical quality attributes, longitudinal monitoring, manufacturing-change comparability, change-impact assessment, evidence escalation, and governance. The architecture distinguishes inherent heterogeneity from uncontrolled variability, transient excursions from directional drift, analytical difference from functional consequence, and functional consequence from clinically meaningful difference. Manufacturing modifications are evaluated through a proposed pathway linking process perturbation to product attributes, biological function, pharmacokinetics, pharmacodynamics, immunogenicity, administration, and plausible clinical consequence. Evidence is escalated according to residual uncertainty and method sensitivity rather than change magnitude alone. Product evolution without loss of clinical continuity is framed as a bounded, traceable conclusion rather than proof of molecular identity, interchangeability, automatic substitution, or universal indication extrapolation. Governance responsibilities include maintenance of product knowledge, assay qualification, model oversight, independent challenge, escalation decisions, and post-change learning. The architecture is an original conceptual synthesis that requires prospective analytical, manufacturing, computational, clinical-pharmacology, immunogenicity, and implementation validation. It does not define universal variability limits, predict clinical outcomes, prescribe regulatory decisions, or establish deployment readiness.
UR  - https://ijpras.com/article/managing-biopharmaceutical-variability-without-demanding-manufacturing-sameness-through-lifecycle-ev-p00cvr1lpq6b7jt
ER  -